A Q&A with BB Biotech's Head of Investment Management Daniel Koller reveals how innovation in medicine is offering investment opportunities.
This month's edition features BB Biotech, one of the largest biotech investors in Europe. A Q&A with Head of Investment Management Daniel Koller reveals how innovation in medicine is offering investment opportunities. Director of Investor Relations at the group, Claude Mikkelsen, meanwhile, offers insight into BB Biotech's investment strategy and how a combination of growth and dividend income can produce favourable investment returns. Focus (Investment Week) is a publication that brings you face to face with a selection of the most in-demand asset managers in the UK and across Europe...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
